

Hepatology COVID-19 Registry  
Week 20 Report

	Liver disease, Non-Transplant (N=48)	Post-liver transplantation (N=46)
<b>Gender (%)</b>	Female = 18 (37.5 %) Male = 30 (62.5 %)	Female = 26 (56.5 %) Male = 20 (43.5 %)
<b>Median Age (yr) at time of COVID diagnosis (range)</b>	9 (0.16-20)	11 (0.5-21)
<b>Etiology of liver disease</b>	NAFLD = 11 Biliary atresia = 11 Autoimmune hepatitis = 8 Acute Liver Failure = 5 Metabolic disorder = 4 Tumor = 2 Others* = 7	Biliary atresia = 15 Acute liver failure = 8 Metabolic disorders = 5 Tumor = 4 Autoimmune hepatitis = 3 Others** = 11
<b>Highest level of care</b>		
Outpatient	13	26
Hospital floor	20	16
ICU	15	4
<b>Immunosuppression at time of COVID diagnosis</b> (*some patients were on multiple agents)	No Immunosuppression = 40 Azathioprine = 7 Steroids = 3	Tacrolimus = 39 Steroids = 17 Mycophenolate Mofetil = 13 Sirolimus = 5 Azathioprine = 3 Everolimus = 4 Cyclosporine = 2
<b>Specific Treatment for COVID</b> (*some patients were on multiple agents)	Hydroxychloroquine = 7 Azithromycin = 6 IVIG = 5 Remdesivir = 5 Steroids = 5 Tocilizumab + Sarilumab = 2 Eculizimab = 3 Convalescent Plasma = 1 Anakinra = 1	Hydroxychloroquine = 2 Azithromycin = 2 IVIG = 1 Favipiravir = 1 Convalescent Plasma = 2 Remdesivir = 1 Steroid (Dexamethasone) = 1
<b>Highest respiratory support</b>		
None	35	44
Nasal cannula/CPAP/BiPAP	6	2
Mechanical ventilation	6	0
High Frequency Oscillatory ventilation	1	0
Pending information	-	-
<b>Final clinical outcome</b>		
Death	1***	0
Recovery	44	44
Still active in clinical course	3	2
Pending information	-	-
<b>Liver related Complications</b>	Ascites = 8 Portal Hypertension Bleeding = 1 Infection = 1	Infection = 1


\*Others CLD: idiopathic cholestasis, GVHD/vanishing bile duct syndrome (Post BMT), IFALD with biliary obstruction, PFIC,PVT

\*\* Others PLT: IFALD , Congenital hepatic fibrosis, Cryptogenic, Neonatal Hepatitis ,H. Hemachromatosis,PHT,Factor V def,

\*\*\*Pulmonary hemorrhage, multi-organ failure


Three recipients had multivisceral transplantation; One PLT recipient also had a transplanted kidney. One had SB+Liver transplant

### Presenting symptoms at time of diagnosis



\*Constitutional symptoms reported: Loss of smell/taste , fever, myalgia, fatigue, sore throat  
# Other symptoms reported: Malaise, anorexia, headache, rash, Kawasaki disease like presentation(MIS-C)

### Change done to Immunosuppressive agent (Post LT)



\*Stopped, decreased the dose, others and No changes  
Commonest agent **stopped**: Mycophenolate Mofetil